Edus H. Warren, MD, PhD
Program Head, Global Oncology
Dr. Edus H. Warren is the Head of Fred Hutch Global Oncology. Dr. Warren, who prefers to go by “Hootie,” assumed leadership of the program in July 2017. Dr. Warren is an oncologist specializing in the treatment of patients with blood cancers such as leukemia, lymphoma, and multiple myeloma. He is an Attending Physician at the Seattle Cancer Care Alliance, where he serves on both the Hematology/Hematologic Malignancy and the Hematopoietic Cell Transplant Services.
Dr. Warren’s research interests are focused on cancer immunotherapy. He has considerable experience as an investigator on clinical trials of novel agents for the treatment of blood cancers, and served as the Principal Investigator on a Phase I clinical trial of T-cell immunotherapy for patients with relapse of acute leukemia or high-grade myelodysplasia after HLA-identical allogeneic hematopoietic cell transplantation. His laboratory research focuses on several interrelated areas, including: high-throughput sequencing of T- and B-cell antigen receptor repertoires; the immunobiology of lymphoma (particularly Burkitt lymphoma and HIV-associated non-Hodgkin lymphoma) and Kaposi sarcoma in sub-Saharan Africa; and solid tumor immunobiology and immunotherapy. High priority objectives of this work are to identify tumor antigens that might be targeted with adoptive T-cell therapy, and to understand how to make solid tumor immunotherapy more effective. Dr. Warren seeks to invest in basic and translational research that will lead to innovative strategies for adapting the advances in cancer research, prevention, diagnosis, and treatment made in high-income countries to help address the increasing burden of cancer morbidity and mortality in low- and middle-income countries.
Warren received a Ph.D. in Neurobiology from Harvard University and a M.D. from Harvard Medical School. He completed a residency in Internal Medicine at Massachusetts General Hospital and a fellowship in Medical Oncology at the University of Washington.